Medication-related osteonecrosis of the jaw

Survey: More Consumers To Prioritize Health This Holiday Season

Retrieved on: 
Wednesday, November 17, 2021

DALLAS, Nov. 17, 2021 /PRNewswire/ --According to a survey conducted by national optical retailer Eyemart Express , consumers plan to spend more time this holiday season focusing on their health.

Key Points: 
  • DALLAS, Nov. 17, 2021 /PRNewswire/ --According to a survey conducted by national optical retailer Eyemart Express , consumers plan to spend more time this holiday season focusing on their health.
  • In fact, 57.1% reported it had been longer than a year since their last eye doctor visit.
  • "It is encouraging that people are including vision health in their focus on wellness," says Katy Hanson Eyemart Express Chief Marketing Officer.
  • Prioritize your eye health at a local Eyemart Express: https://www.eyemartexpress.com/get-glasses .

Medimaps Announces Reimbursement by Center for Medicare and Medicaid Services (CMS) for Trabecular Bone Score for Osteoporosis Fracture Risk Assessment

Retrieved on: 
Thursday, July 29, 2021

This is the first new reimbursable CPT code for fracture risk assessment in osteoporosis in almost a decade.

Key Points: 
  • This is the first new reimbursable CPT code for fracture risk assessment in osteoporosis in almost a decade.
  • The reimbursement amount was released by CMS last week and will become effective and available January 1, 2022.
  • This is largely a result of the fact that 75% of high-risk patients are not being diagnosed timely4.
  • Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study, Journal of Bone and Mineral Research.

Q BioMed Signs License Agreement with Clionix for the Distribution and Sales of Strontium89 in Europe and Middle East

Retrieved on: 
Monday, July 12, 2021

Under the terms of the agreement, Clionix has received exclusive rights to distribute Strontium89 inTurkey, Saudi Arabia,Azerbaijan, Bulgaria, Romania, Egypt, Kuwait& Pakistan.

Key Points: 
  • Under the terms of the agreement, Clionix has received exclusive rights to distribute Strontium89 inTurkey, Saudi Arabia,Azerbaijan, Bulgaria, Romania, Egypt, Kuwait& Pakistan.
  • Over ten million people around the world suffer from pain associated with metastatic cancer in the bone and may benefit from Strontium89.
  • Clionix and Q BioMed will work together to increase the awareness of doctors and patients to the availability of Strontium89.
  • Q BioMed is actively pursuing full regulatory and marketing approval for Strontium89 in thesemarkets as well as in other markets worldwide.

A Review of Antiresorptive Drug Therapy and Dental Implants

Retrieved on: 
Tuesday, June 22, 2021

However, there is little understanding regarding MRONJ risk factors in these patients and whether they contribute to dental implant loss.

Key Points: 
  • However, there is little understanding regarding MRONJ risk factors in these patients and whether they contribute to dental implant loss.
  • Most studies reported (18/22) that resorptive therapy use is safe in patients undergoing dental implant surgery because dental implant failure was low and MRONJ cases were absent.
  • Group 2 included studies of patients with dental implants, a history of taking antiresorptive drugs and presented with MRONJ.
  • The authors provide suggestions as to how clinicians can conduct successful dental implant surgery in patients taking antiresorptive therapies.

Surrozen Publishes Article in Nature Communications Demonstrating Selective Wnt Mimetics Stimulate Bone Mass Accrual in Disease Models of Osteoporosis, Aging and Long-Bone Fracture

Retrieved on: 
Tuesday, June 1, 2021

Surrozen designed an antibody-based platform that generates potent and selective Wnt mimetics and uses this platform to engineer bispecific antibodies that specifically target select tissues.

Key Points: 
  • Surrozen designed an antibody-based platform that generates potent and selective Wnt mimetics and uses this platform to engineer bispecific antibodies that specifically target select tissues.
  • In this paper, the effects of multiple targeted Wnt mimetics, developed through this platform, were evaluated in various disease models of osteoporosis, aging and long-bone fracture to determine the effect on bone repair, bone mass and bone strength.
  • In these disease models, the Wnt agonists induced rapid and robust bone-building effects and corrected bone-mass deficiency and bone defects.
  • The results also suggested that combining Wnt mimetics with current clinical treatments for osteoporosis may enhance bone repair and help maintain bone mass.

Global Bone Cancer Markets, Epidemiology and Patient Flow Report 2020-2035 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 13, 2021

b'The "Global Bone Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Bone Cancer Epidemiology and Patient Flow Analysis - 2021, provides Bone Cancer epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Bone Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Bone Cancer Epidemiology and Patient Flow Analysis - 2021, provides Bone Cancer epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Bone Cancer patients, history of the disease at the population level (Bone Cancer prevalence, Bone Cancer incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Bone Cancer patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Bone Cancer market sizing, assessing market potential, and developing drug forecast models\nIdentify Bone Cancer patients segments through age groups, gender, and disease sub-types\nEvaluate Bone Cancer market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210513005624/en/\n'

Susan G. Komen® and American Bone Health™ Unite on Campaign to Empower Women Through Healthy Living

Retrieved on: 
Wednesday, May 12, 2021

The campaign will target breast cancer survivors, those living with MBC and the general population of women over 45.\n\xe2\x80\x9cWhen it comes to bone health, women need to be their own best advocate.

Key Points: 
  • The campaign will target breast cancer survivors, those living with MBC and the general population of women over 45.\n\xe2\x80\x9cWhen it comes to bone health, women need to be their own best advocate.
  • This campaign will empower women to take the lead in having a conversation about their bones with their health care providers,\xe2\x80\x9d says Cheryl Hostinak, executive director of American Bone Health.
  • The campaign will direct participants to the American Bone Health Fracture Risk CalculatorTM to learn about their risk factors.
  • American Bone Health and American Bone Health Fracture Risk Calculator are trademarks of American Bone Health.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005681/en/\n'

Collaboration to Improve Bone Health Education Published in Cancer Management and Research

Retrieved on: 
Tuesday, May 11, 2021

Multiple Myeloma and Solid Tumor Patients at Risk for Skeletal-Related Events\xe2\x80\x9d in Cancer Management and Research .\nThe paper highlights findings from the Bone Health Education Needs Assessment (BEACON) Study, most notably, gaps in cancer-related bone health education in cancer patients at risk for skeletal-related events (SREs), indicating an important need for improved communication and education strategies to promote better health outcomes.\n\xe2\x80\x9cThe research conducted as part of the BEACON Study will undoubtedly have an impact on the future of bone health education,\xe2\x80\x9d said Darcy Flora, Ph.D., chief research officer at GRYT Health and lead author on the paper.

Key Points: 
  • Multiple Myeloma and Solid Tumor Patients at Risk for Skeletal-Related Events\xe2\x80\x9d in Cancer Management and Research .\nThe paper highlights findings from the Bone Health Education Needs Assessment (BEACON) Study, most notably, gaps in cancer-related bone health education in cancer patients at risk for skeletal-related events (SREs), indicating an important need for improved communication and education strategies to promote better health outcomes.\n\xe2\x80\x9cThe research conducted as part of the BEACON Study will undoubtedly have an impact on the future of bone health education,\xe2\x80\x9d said Darcy Flora, Ph.D., chief research officer at GRYT Health and lead author on the paper.
  • from GRYT Health and Benoit Cadieux, Ph.D., Katherine B. Carlson, Ph.D., Kimberly A. Lowe, Ph.D., and Jennifer Schenfeld, MPH, from Amgen, designed the study to help understand patient awareness of cancer-related bone health and to identify opportunities to improve bone health education in cancer patients at risk of SREs.\nThe online BEACON survey included questions about patient demographics, cancer diagnosis and treatments (including use of a BTA), and extent and satisfaction with bone health education received.
  • Awareness of cancer bone health, protection strategies, and screening tests, however, was low to moderate and patients were least informed of the impact of lifestyle changes (38%) and specific cancer treatments (\xe2\x89\xa435%) on bone health.
  • Additionally, 62% of patients were not completely satisfied with the bone health education they received.

Periodontist Dr. Andres R. Sanchez Enhances Healing for Gum Recession Treatment and Dental Implants in Eden Prairie, MN with Innovative PRF™

Retrieved on: 
Wednesday, May 5, 2021

b'EDEN PRAIRIE, Minn., May 5, 2021 /PRNewswire-PRWeb/ --Periodontist Dr. Andres R. Sanchez leverages PRF (Platelet Rich Fibrin) at PerioWest to enhance healing and minimize pain in patients undergoing surgical procedures such as gum recession treatment and dental implants in Eden Prairie, MN.

Key Points: 
  • b'EDEN PRAIRIE, Minn., May 5, 2021 /PRNewswire-PRWeb/ --Periodontist Dr. Andres R. Sanchez leverages PRF (Platelet Rich Fibrin) at PerioWest to enhance healing and minimize pain in patients undergoing surgical procedures such as gum recession treatment and dental implants in Eden Prairie, MN.
  • Several studies found that PRF reduced postoperative pain and promoted soft tissue and bone healing significantly in patients undergoing tooth extractions.
  • PRF has also proven to increase the healing rate of grafted bone and enhance fusing of dental implants with bone.
  • PerioWest provides state-of-the-art dental implant treatment, LANAP laser therapy, and advanced periodontal care to Eden Prairie, MN and the Twin Cities areas.

Bone Health Technologies Closes $2.5 Million Funding Round and Appoints New Board Members

Retrieved on: 
Monday, May 3, 2021

She brings extensive commercial and technical experience to the board team from a variety of health and medical focused organizations.\nSam Goldberger, MD, MBA brings significant medical expertise to the BHT board.

Key Points: 
  • She brings extensive commercial and technical experience to the board team from a variety of health and medical focused organizations.\nSam Goldberger, MD, MBA brings significant medical expertise to the BHT board.
  • Dr. Goldberger is Co-Founder and Managing Partner of Ambit Health Ventures and has over 28 years of surgical experience.
  • Studies have shown that one 30-minute treatment with OsteoBoost reduced bone loss activity in all study participants.\nFor more information on the CEO appointment or Bone Health Technologies and OsteoBoost please visit: http://www.bonehealthtech.com/\nABOUT BONE HEALTH TECHNOLOGIES:Bone Health Technologies is a San Francisco based company that applies science and medical expertise to create better health outcomes for women and men at risk of developing osteoporosis and the associated bone fractures.
  • Initially created in the med-tech incubator TheraNova, Bone Health Technologies is poised to become the new standard of care in treating both osteoporosis and osteopenia (the precursor to osteoporosis).